Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.
Genmab A/S has completed a share capital reduction approved at its March 19, 2026 Annual General Meeting. The company cancelled 1,900,000 of its own shares, each with a nominal value of DKK 1, reducing the total nominal share capital by DKK 1,900,000.
After this reduction, Genmab’s total share capital is DKK 62,350,721, represented by 62,350,721 shares of DKK 1 each, corresponding to the same number of votes. The change has been registered with the Danish Business Authority and will be reflected in Nasdaq’s systems, which the company expects on April 21, 2026.
Genmab A/S has completed a share capital reduction approved at its March 19, 2026 Annual General Meeting. The company cancelled 1,900,000 of its own shares, each with a nominal value of DKK 1, reducing the total nominal share capital by DKK 1,900,000.
After this reduction, Genmab’s total share capital is DKK 62,350,721, represented by 62,350,721 shares of DKK 1 each, corresponding to the same number of votes. The change has been registered with the Danish Business Authority and will be reflected in Nasdaq’s systems, which the company expects on April 21, 2026.
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S reports a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,221,620 Genmab shares, equal to 5.01% of the company’s share capital and voting rights as of March 31, 2026.
The filing reflects a small increase from a prior 4.99% position and confirms that the holding is via shares only, with no additional voting exposure through financial instruments.
Genmab A/S reports a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,221,620 Genmab shares, equal to 5.01% of the company’s share capital and voting rights as of March 31, 2026.
The filing reflects a small increase from a prior 4.99% position and confirms that the holding is via shares only, with no additional voting exposure through financial instruments.
Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.
Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.